Telix Pharmaceuticals Ltd — Director's Dealing 2023

Mar 16, 2023

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Tiffany Olson
Date of last notice	15 December 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	13-16 March 2023
No. of securities held prior to change	43,930 ordinary shares 52,070 Share Appreciation Rights with a notional exercise price of $4.95 expiring 17 May 2026 (TLXO0014)
Class	Fully paid ordinary shares
Number acquired	51,305
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	51,305 fully paid ordinary shares acquired on market at an average price of $6.693 per share for total consideration paid of $343,385.01

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after 95,235 fully paid ordinary shares change 52,070 Share Appreciation Rights with a notional exercise price of $4.95 expiring 17 May 2026 (TLXO0014)

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback

On-market trade

Part 2 – Change of director’s interests in contracts – NOT APPLICABLE

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts No detailed above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow N/A the trade to proceed during this period? If prior written clearance was provided, on what N/A date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011